Related Experiment Video
Updated: Jul 27, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Implementing Promising Strategies to Reduce the Risk for Viral Hepatitis and Liver Cancer Among People Who Inject
Behnoosh Momin1, Jennifer Mezzo2, Danielle Nielsen2
1Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Purpose:
To describe a 3-year demonstration project with selected Centers for Disease Control and Prevention National Comprehensive Cancer Control Program (NCCCP) award recipients to build partnerships with local organizations to improve knowledge and awareness of the association between injecting drugs and the risk for viral hepatitis and liver cancer, improve delivery of viral hepatitis services, and implement comprehensive syringe services programs.
Design:
A mixed-methods descriptive evaluation of selected evidence-based interventions or promising strategies that each award recipient implemented based on the needs of their population.
Setting:
Selected provider and patient populations served by NCCCP award recipients in Iowa, Minnesota (American Indian Cancer Foundation), Mississippi, and West Virginia.
Subjects:
Four award recipients that implemented individually-tailored strategies and activities.
Measures:
Processes were assessed through monitoring and tracking tools. Challenges, lessons learned, and recommendations were collected via qualitative interviews.
Analysis:
We used descriptive statistics to analyze quantitative data. We analyzed award recipient interviews using thematic analysis.
Results:
Activities were implemented across four strategies. Strong public-private partnerships, ongoing technical assistance, a deep understanding of individual populations, and a shared commitment to remaining flexible were main factors.
Conclusion:
While challenges existed, award recipients implemented key strategies and activities in their populations. Findings contribute to the scaling of best practices to the larger cancer control community especially those whose populations are at higher risk for viral hepatitis.
Insights
This project improved awareness of injecting drug risks for viral hepatitis and liver cancer. It successfully implemented strategies to enhance viral hepatitis services and syringe programs in diverse populations.
Area of Science:
- Public Health
- Cancer Control
- Infectious Disease Epidemiology
Background:
- Injecting drug use is a significant risk factor for viral hepatitis and liver cancer.
- Comprehensive cancer control programs are essential for addressing health disparities.
- Effective partnerships are crucial for implementing public health interventions.
Purpose of the Study:
- To describe a 3-year demonstration project involving Centers for Disease Control and Prevention National Comprehensive Cancer Control Program (NCCCP) award recipients.
- To build local partnerships to increase awareness of the link between injecting drug use, viral hepatitis, and liver cancer.
- To improve viral hepatitis service delivery and implement syringe services programs.
Main Methods:
- A mixed-methods descriptive evaluation was conducted.
- Four NCCCP award recipients implemented tailored, evidence-based interventions.
- Processes were monitored, and qualitative interviews assessed challenges and lessons learned.
Main Results:
- Award recipients implemented key strategies and activities across four main areas.
- Strong public-private partnerships, technical assistance, and population-specific understanding were critical success factors.
- Flexibility and a commitment to collaboration facilitated program implementation.
Conclusions:
- Despite challenges, award recipients successfully implemented vital strategies.
- Findings support the scaling of best practices for cancer control, particularly for high-risk populations.
- This project highlights the importance of integrated approaches to address viral hepatitis and cancer risks associated with injecting drug use.
More Related Videos
07:25Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
Retrovirus Life Cycles
Prevention of Further Absorption of Poison
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Sexually Transmitted Infections
Viruses with RNA Genomes